
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris
Cenerimod is a novel oral S1P1 receptor modulator with potential to be a first- or best-in-class therapy for multiple autoimmune diseases Viatris previously acquired rights to cenerimod in all other territories from Idorsia, and now has exclusive global …